"Fondée en 1919, la Clinique Convert est installée sur son site actuel depuis 1974. Depuis, l'établissement du groupe Ramsay Santé n'a eu de cesse d'apporter les meilleurs soins à travers ses agrandissements et les évolutions de son plateau technique. En 2015, la clinique a accueilli près de 20 000 patients et réalisé 13 304 interventions au bloc opératoire. Elle a également accueilli 17 570 premiers passages aux urgences, 2 993 séances de chimiothérapie, 1 486 actes en cardiologie interventionnelle et 4 431 journées en réanimation. L’établissement dispose de 160 lits et places."

During the past decade, Clinique Convert conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinique Convert" #1 sponsor was "Biotronik AG" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Hospira, now a wholly owned subsidiary of Pfizer" with 2 trials sponsored, "Alvimedica Medical Technologies France" with 1 trials sponsored and "Centre Hospitalier Annecy Genevois" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinique Convert" #1 collaborator was "Biotronik France" with 1 trials as a collaborator, "EVAMED" with 1 trials as a collaborator, "Floralis" with 1 trials as a collaborator, "Société Française d'Anesthésie et de Réanimation" with 1 trials as a collaborator and "University Hospital, Grenoble" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Clinique Convert" are "Colorectal Cancer" (2 trials), "Acute Coronary Syndrome" (1 trials), "Chemotherapy-induced Anemia" (1 trials), "Chemotherapy-induced Febrile Neutropenia (FN)" (1 trials) and "Coronaropathy" (1 trials). Many other conditions were trialed in "Clinique Convert" in a lesser frequency.

Most popular intervention types in "Clinique Convert" are "Device" (4 trials), "Drug" (2 trials), "Other" (2 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "1 year follow-up to assess psychiatric morbidity" (1 trials), "6 months follow-up to assess the prevalence of PTSD symptoms" (1 trials), "Administration of the IPREA3 questionnaire" (1 trials), "Bevacizumab" (1 trials) and "Bivalirudin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Clinique Convert" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Clinique Convert". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Clinique Convert, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Clinique Convert, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".